Previous 10 | Next 10 |
B usiness to prioritize high- potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease Commercial reprioritization intended to reduce related expenses by 80% with focus on market access throu...
2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...
2023-08-11 11:59:24 ET BioXcel Therapeutics ( NASDAQ: BTAI ) is scheduled to announce Q2 earnings results on Monday, August 14th, before market open. The consensus EPS Estimate is -$1.73 and the consensus Revenue Estimate is $0.47M. Over the last 1 year, BTAI has bea...
NEW YORK, NY / ACCESSWIRE / August 8, 2023 / Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ:BTAI) of a class action securities lawsuit. The lawsuit on behalf of BioXcel investors has been commenced in the United States District ...
2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...
NEW HAVEN, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its second quarter ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 10, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased the securities of BioXcel Therapeutics, ...
ATLANTA, July 10, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioXcel Therapeutics, Inc. (“BioXcel,” or the “Company”) (NASDAQ: BTAI) complied with federal securities laws. On June 29, 2023, the Company disclosed that it is c...
2023-07-07 08:16:18 ET What a difference a week can make to a volatile stock. Following a significant swoon late last week, BioXcel Therapeutics (NASDAQ: BTAI) sharply reversed course in the subsequent frame. As of early Friday morning, according to data compiled by S&P Global...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...